Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study aims to uncover hidden health differences in rare lung infections

NCT ID NCT07192705

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 80 adults—40 with NTM lung disease (not on antibiotics) and 40 with bronchiectasis alone—to see if their health needs differ. Using questionnaires and simple physical tests, researchers will assess quality of life, nutrition, mood, and muscle strength. The goal is to better understand what non-drug support (like exercise or diet advice) might help each group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal specific health needs of people with NTM lung disease, leading to better non-drug treatments like exercise or nutrition support.
What could go wrong
This is a small, observational study at one center, so results may not apply to everyone. It does not test any treatment, so it won't directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Participants diagnosed with NTM-PD. * Participants diagnosed with bronchiectasis without NTM pulmonary infection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Age: 18 years or older, able to provide informed consent. NTM-PD Group: * Participants will be adults diagnosed with confirmed NTM-PD based on the British Thoracic Society (BTS) guidelines. * The participant should not be on any antimicrobial therapy (at least two weeks before participation) and should not have previously received or be currently on antimicrobial therapy for NTM-PD. \* BTS guidelines: * Clinical (both required): * Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CT scan that shows multifocal bronchiectasis with multiple small nodules. * Appropriate exclusion of other diagnoses. * Microbiological: * A minimum of two positive expectorated sputum culture results of the same NTM species from samples collected on separate days within 12 months before recruitment. OR * Positive culture results from at least one bronchial wash or lavage. OR * Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM. Bronchiectasis Group: * Diagnosed with bronchiectasis, as confirmed in medical records based on clinical assessment, and radiological findings. * Never had a history of positive culture result for NTM pulmonary infection. * The latest NTM-negative result must be within the past 12 months from the study's start date or no earlier than 2024. Exclusion Criteria: \- Age: Under 18 years of age, or unable to provide informed consent. NTM-PD Group: * No confirmation of NTM-PD diagnosis. * Diagnosed with a reinfection of NTM-PD. * Started antimicrobial therapy for NTM-PD. Bronchiectasis Group: * No diagnosis of bronchiectasis or diagnosis of bronchiectasis with NTM-PD. * Diagnosed with other chronic respiratory diseases considered primary conditions, rather than bronchiectasis. * Participants with a history of NTM pulmonary infection. * NTM-negative results obtained before 2024.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchiectasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Free London NHS Foundation Trust

    RECRUITING

    London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.